Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rademikibart (CBP-201) in Chinese subjects with moderate to severe atopic dermatitis
NCT05017480Phase 2Completed
- Sponsor
- Connect Biopharma
- Start
- Aug 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Rademikibart (CBP-201) with Placebo (2 arms). Primary endpoint: Investigator Global Assessment 0 or 1 at 16 weeks. Started Aug 2021; status: completed.
02
Drugs
rademikibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05017480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05017480.